GLPGF — Lakefront Biotherapeutics NV

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1421876 · Belgium
Last close
$35.15
Market Cap
$2.30B
52W High
$35.15
52W Low
$26.24
ADV30
3
Next earnings
2026-11-11

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 7,578,000 3,901,000 -41,172,000 -2,671,000 3,294,568,000 94,655,000 61,806,000
Jun 2026 12,110,000 2,965,000 -43,511,000 2,109,000 3,351,188,000 135,952,000 87,558,000
Mar 2026 6,481,000 1,682,000 -63,703,000 14,492,000 3,372,429,000 66,805,000 119,060,000
Dec 2025 900,822,000 900,367,000 758,798,000 782,146,000 3,406,518,000 87,868,000 170,650,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-226,909,000
Investing CF
$292,276,000
Financing CF
$-6,110,000
CapEx
$-4,606,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.11
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$233,958,000
Inventory
$8,544,000
Receivables
$56,296,000
ST Investments
$2,103,597,000
EBIT TTM
$579,011,000
Pretax Income TTM
$577,632,000
Interest Exp TTM
—
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$990,574,016
EBITDA
$568,918,016
Free Cash Flow
$138,206,256
Enterprise Value
$-510,395,424
Total Cash
$2,239,548,928
Total Debt
$6,362,000
Shares Out
65,484,670
Trailing EPS
$10.49
Book Value
$57.73
ROE
20.1%
ROA
9.9%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,112,248,000 501,391,000 320,884,000 3,406,518,000 170,650,000 3,235,868,000 -257,456,000
Dec 2024 275,649,000 -188,338,000 74,082,000 4,135,719,000 1,238,780,000 2,896,939,000 -320,026,000
Dec 2023 239,724,000 -88,263,000 211,697,000 4,357,396,000 1,561,830,000 2,795,566,000 -405,970,000
Dec 2022 241,249,000 -131,057,000 -217,991,000 4,734,351,000 2,208,325,000 2,526,026,000 -500,544,000

Peers — same industry

TickerNameMarket CapLastDaily %
PBH Prestige Consumer Healthcare Inc. $2.29B $48.22 —
NAMS NewAmsterdam Pharma Co N.V. $2.33B $19.39 —
PHVS Pharvaris N.V. $2.27B $32.28 —
LKFT Lakefront Biotherapeutics NV $2.25B $34.39 —
RCUS Arcus Biosciences, Inc. $2.36B $16.39 —

News headlines (Yahoo Finance, 1h cache)

Lakefront Creates New Subscription Right Plan
2026-11-18 21:01 · Yahoo
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program
2026-11-16 06:30 · Yahoo
Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update
2026-11-11 21:01 · Yahoo
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London
2026-11-10 21:01 · Yahoo
Is Lakefront Biotherapeutics (ENXTAM:LKFT) Cheap Given Its Earnings Today?
2026-11-10 14:12 · Yahoo
Should You Buy Lakefront Biotherapeutics - Sponsored ADR (LKFT) After Golden Cross?
2026-11-06 13:55 · Yahoo
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
2026-11-04 14:01 · Yahoo
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors
2026-11-02 21:01 · Yahoo
Lakefront Biotherapeutics - Sponsored ADR (LKFT) Upgraded to Buy: What Does It Mean for the Stock?
2026-10-21 15:00 · Yahoo
Lakefront Biotherapeutics (ENXTAM:LKFT) Stock Looks Undervalued Despite A 40% Five Year Fall
2026-10-21 05:16 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.